Xtandi Before Chemotherapy Gets Favorable Results In Final Phase Trial
This article was originally published in PharmAsia News
Executive Summary
Xtandi (enzalutamide), a prostate-cancer drug of Astellas Pharma and Medivation, has shown significant increases in survival for patients prior to chemotherapy in a Phase III trial.